Confronto
Octreotide vs. Teduglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
83150-76-9
197922-42-2
Peso molecolare
1019.24 g/mol
3752.13 g/mol
Emivita
1.7 h
nessun dato
Sequenza
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)nessun dato
Meccanismo d'azione
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
2
di cui sull'uomo
4
2
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Octreotide and Teduglutid?
- Octreotide is classified as "Ricerca (altro)", while Teduglutid is classified as "Ricerca (altro)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Octreotide or Teduglutid?
- The highest available evidence level is "RCT sull'uomo" for Octreotide and "RCT sull'uomo" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Octreotide and Teduglutid in Germany and the United States?
- Germania: Octreotide — Su prescrizione, Teduglutid — Su prescrizione. Stati Uniti: Octreotide — Su prescrizione, Teduglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.